FDA Oncology Drug Reviews Headed By Justice Under Revised Structure
Executive Summary
Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs
You may also be interested in...
FDA oncology division director
FDA appoints Robert Justice as director of the Division of Drug Oncology Products within FDA's Office of Oncology Drug Products, effective June 11. Justice had been acting director of the division since it became operational as part of a July 2005 CDER reorganization (1"The Pink Sheet" June 27, 2005, p. 11). Justice has held several positions within the agency since 1985 and was a senior clinical scientist at Genentech from 2000-2002...
FDA oncology division director
FDA appoints Robert Justice as director of the Division of Drug Oncology Products within FDA's Office of Oncology Drug Products, effective June 11. Justice had been acting director of the division since it became operational as part of a July 2005 CDER reorganization (1"The Pink Sheet" June 27, 2005, p. 11). Justice has held several positions within the agency since 1985 and was a senior clinical scientist at Genentech from 2000-2002...
Cancer Prevention Drugs Require Protocol Assessment Before Phase III – FDA
All oncologic risk reduction drugs should have a special protocol assessment (SPA) before entering Phase III trials, FDA advises staff in a recently issued "Manual of Policies and Procedures" guidance